普拉克索治疗帕金森病患者非运动症状随机对照临床试验

发布时间：2019-03-09 08:44

【摘要】：目的观察普拉克索治疗帕金森病(PD)患者非运动症状的临床疗效。方法将PD非运动症状患者102例随机分为对照组50例和试验组52例,对照组患者给予多巴丝肼治疗,试验组患者在对照组基础上加用普拉克索治疗,两组患者均以连续服用12周为1个疗程。采用非运动症状筛查问卷(NMSQuest)、汉密尔顿抑郁量表(HAMD)、帕金森病睡眠量表(PDSS)、简易精神状态量表(MMSE)及帕金森病自主神经症状量表(SCOPA-AUT)对患者的非运动症状发生情况、抑郁状况、睡眠状况、认知功能及自主神经功能障碍程度进行评定。结果试验组NMSQuest总分、HAMD及PDSS评分均较对照组显著改善(P0.05),而MMSE与SCOPA-AUT评分两组间无统计学差异(P0.05)。结论普拉克索能改善PD患者的部分非运动症状,如抑郁状态和睡眠障碍,但对认知功能和自主神经功能障碍无明显改善作用。
[Abstract]:Objective to observe the clinical efficacy of praxol in the treatment of non-motor symptoms in patients with Parkinson's disease (PD). Methods 102 patients with non-motor symptoms of PD were randomly divided into control group (n = 50) and test group (n = 52). The patients in the control group were treated with doxyhydrazine, and the patients in the test group were treated with praxol on the basis of the control group. Patients in both groups were given 12 weeks as a course of treatment. Non-motor symptom screening questionnaire (NMSQuest), Hamilton depression scale (HAMD), Parkinson's disease sleep scale (PDSS), Mini-mental state scale (MMSE) and Parkinson's disease autonomic neurosis scale (SCOPA-AUT) were used to evaluate the incidence of non-motor symptoms, depression, sleep status, cognitive function and degree of autonomic nervous dysfunction. Results the total scores of NMSQuest, HAMD and PDSS in the experimental group were significantly improved compared with those in the control group (P0.05), but there was no significant difference between the two groups in MMSE and SCOPA-AUT scores (P0.05). Conclusion Praxol can improve some non-motor symptoms such as depression and sleep disorder in patients with PD, but it has no effect on cognitive function and autonomic nervous dysfunction.
【作者单位】：重庆市第九人民医院;
【基金】：重庆市卫生局医学科研项目;项目编号:渝卫科教[2014]56号:20142175
【分类号】：R742.5

【相似文献】